Rachel Humphrey

Los Angeles County Department of Public Health — United States

Medicine · Health Sciences

27h-index11.7kcitations72works12.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(26), Immunotherapy and Immune Responses(24), CAR-T cell therapy research(21), Peptidase Inhibition and Analysis(11), Protease and Inhibitor Mechanisms(9)

Publications72 total

Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
Science Immunology·2024· 21 cited
Creating and Implementing a Community-Focused, Culturally Tailored Health Marketing Campaign to Address Menthol Cigarette Use in Los Angeles County
Preventing Chronic Disease·2024· 3 citedOpen Access
CCR Translation for the Article from Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2023Open Access
Data from Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
2023Open Access
CCR Translation for the Article from Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2023Open Access
Supplementary Table and Figures from Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
2023Open Access
Data from Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2023Open Access
Data from Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2023Open Access
Data from Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
2023Open Access
Supplementary Table and Figures from Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
2023Open Access
Down-regulation of <i>Drosophila</i> Glutactin, a cholinesterase-like adhesion molecule of the basement membrane, impairs development, compromises adult function and shortens lifespan
2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
Journal for ImmunoTherapy of Cancer·2022· 15 citedOpen Access
Abstract P02-04: BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat osimertinib-resistant NSCLC with or without brain metastases
Molecular Cancer Therapeutics·2021· 3 cited
Clinical pharmacokinetics of bdtx-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study.
Journal of Clinical Oncology·2021· 5 cited
Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric <i>ErbB</i> mutations, in patients (pts) with advanced solid malignancies.
Journal of Clinical Oncology·2021· 17 cited
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Journal for ImmunoTherapy of Cancer·2020· 261 citedOpen Access
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
Clinical Cancer Research·2019· 168 citedOpen Access
UNDERSTANDING AND FOSTERING INTERACTION IN THREADED DISCUSSION
Online Learning·2019· 7 citedOpen Access
Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors
Annals of Oncology·2018· 2 citedOpen Access
Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors
Annals of Oncology·2018· 2 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Axel Hoos(13), Steven O’Day(7), Jeffrey S. Weber(7), Michele Maio(7), Jedd D. Wolchok(7), Kaan Harmankaya(6), Ramy Ibrahim(6), Robert Yarchoan(6), F. Stephen Hodi(5), Célèste Lebbé(4), J. D. Wolchok(4), Hubert Pehamberger(4), Kevin M. Chin(4), David A. Davis(4), Omid Hamid(3), Vanna Chiarion‐Sileni(3), David M. Berman(3), Karen A. Autio(3), Aung Naing(3), V. DePril(3)